Review

rta 408 (MedChemExpress)

Name: rta 408
Brand: MedChemExpress
Rating: 94 (32 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress rta 408
Rta 408, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 32 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rta 408/product/MedChemExpress
Average 94 stars, based on 32 article reviews

rta 408 - by Bioz Stars, 2026-03

94/100 stars

Images

Image Search Results

Omaveloxolone inhibited the growth of GBM cells in a time‐ and dose‐dependent manner. (A) Cell viability of omaveloxolone‐treated glioma cells from 24 to 72 h. GBM cells were treated with different concentrations of omaveloxolone (0, DMSO, 100, 200, 400, 600, 800, 1000 and 1200 nM) for 24–72 h. Control cells were exposed to DMSO. Cell viability was measured through a cell viability assay with the PrestoBlue Cell Viability Reagent. (B) The IC 50 values of omaveloxolone‐treated GBM8401 and U‐87 MG cells at different time points (24 h, 48 h and 72 h). (C) Morphology of GBM8401 and U‐87 MG cells after treatment with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. (D) Live cell tomographic microscopy images of GBM8401 and U‐87 MG cells treated and untreated with omaveloxolone (800 nM), as observed under a 3D tomographic microscope equipped with a 60× objective. The results are expressed as mean ± standard deviation (SD) of three independent experiments. **** p < 0.00001 compared with the control group (DMSO).

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Omaveloxolone inhibited the growth of GBM cells in a time‐ and dose‐dependent manner. (A) Cell viability of omaveloxolone‐treated glioma cells from 24 to 72 h. GBM cells were treated with different concentrations of omaveloxolone (0, DMSO, 100, 200, 400, 600, 800, 1000 and 1200 nM) for 24–72 h. Control cells were exposed to DMSO. Cell viability was measured through a cell viability assay with the PrestoBlue Cell Viability Reagent. (B) The IC 50 values of omaveloxolone‐treated GBM8401 and U‐87 MG cells at different time points (24 h, 48 h and 72 h). (C) Morphology of GBM8401 and U‐87 MG cells after treatment with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. (D) Live cell tomographic microscopy images of GBM8401 and U‐87 MG cells treated and untreated with omaveloxolone (800 nM), as observed under a 3D tomographic microscope equipped with a 60× objective. The results are expressed as mean ± standard deviation (SD) of three independent experiments. **** p < 0.00001 compared with the control group (DMSO).

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Control, Viability Assay, Microscopy, Standard Deviation

Omaveloxolone reduced the colony formation ability of GBM cells. (A) Colony formation assays of GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. These cells were stained with crystal violet. (B) PI staining assay was conducted to examine cell death in GBM cells treated with different concentrations of omaveloxolone for 24 h (BF: Bright field, PI: Propidium iodide). (C) Cells were treated with omaveloxolone (0, 600 and 800 nM), and their nuclei were stained for α‐tubulin (red) and DAPI (blue) under a confocal microscope. Data are expressed as mean ± SD of 3 independent experiments. * p < 0.5, ** p < 0.001 and *** p < 0.0001 compared with the control group.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Omaveloxolone reduced the colony formation ability of GBM cells. (A) Colony formation assays of GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. These cells were stained with crystal violet. (B) PI staining assay was conducted to examine cell death in GBM cells treated with different concentrations of omaveloxolone for 24 h (BF: Bright field, PI: Propidium iodide). (C) Cells were treated with omaveloxolone (0, 600 and 800 nM), and their nuclei were stained for α‐tubulin (red) and DAPI (blue) under a confocal microscope. Data are expressed as mean ± SD of 3 independent experiments. * p < 0.5, ** p < 0.001 and *** p < 0.0001 compared with the control group.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Staining, Microscopy, Control

Effect of omaveloxolone on the migration and invasion of glioma cells. (A) Migration ability detected for GBM8401 and U‐87 MG cells treated with omaveloxolone through a wound healing assay. (B) Invasion ability detected for GBM8401 and U‐87 MG cells treated with omaveloxolone through a Transwell invasion assay. Data are expressed as mean ± SD of 3 independent experiments. * p < 0.5, ** p < 0.001 and *** p < 0.0001 compared with the control group.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Effect of omaveloxolone on the migration and invasion of glioma cells. (A) Migration ability detected for GBM8401 and U‐87 MG cells treated with omaveloxolone through a wound healing assay. (B) Invasion ability detected for GBM8401 and U‐87 MG cells treated with omaveloxolone through a Transwell invasion assay. Data are expressed as mean ± SD of 3 independent experiments. * p < 0.5, ** p < 0.001 and *** p < 0.0001 compared with the control group.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Migration, Wound Healing Assay, Transwell Invasion Assay, Control

Omaveloxolone regulated the cell cycle phases of GBM cells. (A) Cell cycle analysis of GBM8401 and U‐87 MG cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h through flow cytometry analysis. (B) Analysis of cell cycle distribution (G1, S and G2/M) in GBM8401 and U‐87 MG cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. Cells were stained with PI and analysed using flow cytometry.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Omaveloxolone regulated the cell cycle phases of GBM cells. (A) Cell cycle analysis of GBM8401 and U‐87 MG cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h through flow cytometry analysis. (B) Analysis of cell cycle distribution (G1, S and G2/M) in GBM8401 and U‐87 MG cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. Cells were stained with PI and analysed using flow cytometry.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Cell Cycle Assay, Flow Cytometry, Staining

Omaveloxolone increased the apoptosis and regulated the MMP of GBM cells. (A) Representative cell apoptosis of GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 4 h. Total apoptosis of GBM cells detected by flow cytometry. (B) Representative MMP of GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 4 h. The data indicate decreased apoptosis in GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) with JC‐1 staining.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Omaveloxolone increased the apoptosis and regulated the MMP of GBM cells. (A) Representative cell apoptosis of GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 4 h. Total apoptosis of GBM cells detected by flow cytometry. (B) Representative MMP of GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) for 4 h. The data indicate decreased apoptosis in GBM cells treated with omaveloxolone (0, 600, 800 and 1000 nM) with JC‐1 staining.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Flow Cytometry, Staining

Effect of omaveloxolone on cell cycle‐related protein expression. Omaveloxolone regulated the expression of cell cycle‐related proteins in GBM cells. Both cell types were treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. Subsequently, the pellets were collected, and the lysates were isolated using lysis buffer. The results indicated that treatment with omaveloxolone regulated cell cycle‐related proteins in GBM8401 and U‐87 MG cells. The expression of cyclin D1, CDK4, CDK6, cyclin B1, CDK1 and p21 was analysed using immunoblotting. β‐Actin was used as the loading control.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Effect of omaveloxolone on cell cycle‐related protein expression. Omaveloxolone regulated the expression of cell cycle‐related proteins in GBM cells. Both cell types were treated with omaveloxolone (0, 600, 800 and 1000 nM) for 24 h. Subsequently, the pellets were collected, and the lysates were isolated using lysis buffer. The results indicated that treatment with omaveloxolone regulated cell cycle‐related proteins in GBM8401 and U‐87 MG cells. The expression of cyclin D1, CDK4, CDK6, cyclin B1, CDK1 and p21 was analysed using immunoblotting. β‐Actin was used as the loading control.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Expressing, Isolation, Lysis, Western Blot, Control

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Verification of gene expression in GBM cells treated with omaveloxolone. (A) GeneRatio dot plot of the KEGG pathway analysis of GBM cells treated with omaveloxolone. (B) Heatmap clustering analysis of differential transcripts per million genes following GBM cell treatment with omaveloxolone. (C) Volcano plot of cell cycle‐related gene downregulation or upregulation in GBM cells following treatment with omaveloxolone. Gene log‐fold change (log Fc) expression profile after treatment with omaveloxolone at 800 nM.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Gene Expression, Expressing

High expression of CDC20 was associated with poor prognosis in patients with GBM. Box plot of the analysis of CDC20 expression in patients with GBM in (A) DriverDBv4 and (B) GEPIA 2 software. (C) Representative TMA data of CDC20 expression in brain cancer (N, normal, n = 10; A: Astrocytoma, n = 42; GBM, glioblastoma, n = 24). (D) Omaveloxolone decreased the expression of CDC20 using immunoblotting. Data are expressed as mean ± SD. * p < 0.05 and **** p < 0.0001. ns, no significant difference.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: High expression of CDC20 was associated with poor prognosis in patients with GBM. Box plot of the analysis of CDC20 expression in patients with GBM in (A) DriverDBv4 and (B) GEPIA 2 software. (C) Representative TMA data of CDC20 expression in brain cancer (N, normal, n = 10; A: Astrocytoma, n = 42; GBM, glioblastoma, n = 24). (D) Omaveloxolone decreased the expression of CDC20 using immunoblotting. Data are expressed as mean ± SD. * p < 0.05 and **** p < 0.0001. ns, no significant difference.

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Expressing, Software, Western Blot

Antitumor activity of omaveloxolone in vivo. (A) Schematic of the experimental subcutaneous GBM8401 tumour model with omaveloxolone treatment. Experiments were conducted using 4‐week‐old male nude mice (BALB/c‐nu). When tumours sizes reached 10–20 mm 3 , an intraperitoneal injection of omaveloxolone (15, 20 or 25 mg/kg, with 0.1% DMSO as control) was administered for 4 weeks. (B) Effect of omaveloxolone tumour volume in mouse xenografts. (C) Effect of omaveloxolone on the body weight of nude mice. (D) CDC20 and H&E‐stained sections from tumours in nude mice treated with omaveloxolone (15, 20 and 25 mg/kg) and the control group. Data are expressed as mean ± SEM ( n = 5). * p < 0.05, ** p < 0.001 and *** p < 0.0001 compared with the control group. This figure was created using BioRender.com .

Journal: Journal of Cellular and Molecular Medicine

Article Title: Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo

doi: 10.1111/jcmm.70607

Figure Lengend Snippet: Antitumor activity of omaveloxolone in vivo. (A) Schematic of the experimental subcutaneous GBM8401 tumour model with omaveloxolone treatment. Experiments were conducted using 4‐week‐old male nude mice (BALB/c‐nu). When tumours sizes reached 10–20 mm 3 , an intraperitoneal injection of omaveloxolone (15, 20 or 25 mg/kg, with 0.1% DMSO as control) was administered for 4 weeks. (B) Effect of omaveloxolone tumour volume in mouse xenografts. (C) Effect of omaveloxolone on the body weight of nude mice. (D) CDC20 and H&E‐stained sections from tumours in nude mice treated with omaveloxolone (15, 20 and 25 mg/kg) and the control group. Data are expressed as mean ± SEM ( n = 5). * p < 0.05, ** p < 0.001 and *** p < 0.0001 compared with the control group. This figure was created using BioRender.com .

Article Snippet: Omaveloxolone (RTA 408, CAS no. 1474034‐05‐3) was obtained from Cayman Chemicals.

Techniques: Activity Assay, In Vivo, Injection, Control, Staining

RTA-408 alleviates liver injury and improves liver function in HIRI mice. Serum (a) and (b) ALT and AST levels in each group, n = 6. (c) and (d) H&E staining and Suzuki’s score for the morphology examination of mice liver samples, n = 3, (×200). ## P < 0.01 vs Sham group, ** P < 0.01 vs HIRI group.

Journal: Open Life Sciences

Article Title: RTA-408 attenuates the hepatic ischemia reperfusion injury in mice possibly by activating the Nrf2/HO-1 signaling pathway

doi: 10.1515/biol-2025-1093

Figure Lengend Snippet: RTA-408 alleviates liver injury and improves liver function in HIRI mice. Serum (a) and (b) ALT and AST levels in each group, n = 6. (c) and (d) H&E staining and Suzuki’s score for the morphology examination of mice liver samples, n = 3, (×200). ## P < 0.01 vs Sham group, ** P < 0.01 vs HIRI group.

Article Snippet: One day before the hepatic ischemia, mice in the HIRI + RTA-408 group were intraperitoneally injected with 100 μg/kg RTA-408 (MedChemExpress, USA).

Techniques: Staining

RTA-408 reduces the HIRI-induced inflammatory reaction, cell apoptosis, and oxidative stress in mice. (a) and (b) The ratio of MPO-positive in mice hepatic tissues were evaluated by IHC, (×200). (c) and (d) MDA content and SOD activities in mice hepatic tissues. (e) and (f) TUNEL staining was conducted to assess the hepatic apoptosis of mice in indicated groups, n = 3, (×200). ## P < 0.01and # P < 0.05 vs Sham group, ** P < 0.01 vs HIRI group.

Journal: Open Life Sciences

Article Title: RTA-408 attenuates the hepatic ischemia reperfusion injury in mice possibly by activating the Nrf2/HO-1 signaling pathway

doi: 10.1515/biol-2025-1093

Figure Lengend Snippet: RTA-408 reduces the HIRI-induced inflammatory reaction, cell apoptosis, and oxidative stress in mice. (a) and (b) The ratio of MPO-positive in mice hepatic tissues were evaluated by IHC, (×200). (c) and (d) MDA content and SOD activities in mice hepatic tissues. (e) and (f) TUNEL staining was conducted to assess the hepatic apoptosis of mice in indicated groups, n = 3, (×200). ## P < 0.01and # P < 0.05 vs Sham group, ** P < 0.01 vs HIRI group.

Article Snippet: One day before the hepatic ischemia, mice in the HIRI + RTA-408 group were intraperitoneally injected with 100 μg/kg RTA-408 (MedChemExpress, USA).

Techniques: TUNEL Assay, Staining

RTA-408 reduces the HIRI-induced cell apoptosis in mice liver tissues. (a) and (b) Bax, Bcl-2, and cleaved caspase-3 protein levels in mice liver samples were examined using western blot. RTA-408 activated the Nrf2/HO-1 pathway in vivo . (c) and (d) The protein levels of Nrf2 and HO-1 in mice hepatic tissues were assessed by western blot, n = 3. ## P < 0.01 vs Sham group, ** P < 0.01 and * P < 0.05 vs HIRI group.

Journal: Open Life Sciences

Article Title: RTA-408 attenuates the hepatic ischemia reperfusion injury in mice possibly by activating the Nrf2/HO-1 signaling pathway

doi: 10.1515/biol-2025-1093

Figure Lengend Snippet: RTA-408 reduces the HIRI-induced cell apoptosis in mice liver tissues. (a) and (b) Bax, Bcl-2, and cleaved caspase-3 protein levels in mice liver samples were examined using western blot. RTA-408 activated the Nrf2/HO-1 pathway in vivo . (c) and (d) The protein levels of Nrf2 and HO-1 in mice hepatic tissues were assessed by western blot, n = 3. ## P < 0.01 vs Sham group, ** P < 0.01 and * P < 0.05 vs HIRI group.

Article Snippet: One day before the hepatic ischemia, mice in the HIRI + RTA-408 group were intraperitoneally injected with 100 μg/kg RTA-408 (MedChemExpress, USA).

Techniques: Western Blot, In Vivo

The effects of RTA-408 on HIRI in Nrf2−/− mice. Serum (a) ALT and (b) AST levels in Nrf2−/− mice subjected to indicated treatment. (c) and (d) H&E staining and Suzuki’s score for the morphology examination of mice liver samples, n = 3, (×200).

Journal: Open Life Sciences

Article Title: RTA-408 attenuates the hepatic ischemia reperfusion injury in mice possibly by activating the Nrf2/HO-1 signaling pathway

doi: 10.1515/biol-2025-1093

Figure Lengend Snippet: The effects of RTA-408 on HIRI in Nrf2−/− mice. Serum (a) ALT and (b) AST levels in Nrf2−/− mice subjected to indicated treatment. (c) and (d) H&E staining and Suzuki’s score for the morphology examination of mice liver samples, n = 3, (×200).

Article Snippet: One day before the hepatic ischemia, mice in the HIRI + RTA-408 group were intraperitoneally injected with 100 μg/kg RTA-408 (MedChemExpress, USA).

Techniques: Staining

Review

Structured Review

Images

Similar Products

Image Search Results